Predict your next investment

United BioSource company logo
Corporation
HEALTHCARE | Medical Facilities & Services / Medical Laboratories & Research
ubc.com

See what CB Insights has to offer

Founded Year

2003

Stage

Private Equity - IV | Alive

Total Raised

$439.17M

Last Raised

$11.17M | 2 yrs ago

About United BioSource

United BioSource Corporation is a global pharmaceutical services organization that aims to help emerging and established life science companies develop and commercialize medical products. UBC specializes in providing new ways to study drugs and devices by offering expertise in science, strategy and execution.

United BioSource Headquarter Location

920 Harvest Drive

Blue Bell, Pennsylvania, 19422,

United States

215-591-2880

Latest United BioSource News

Former Astellas Pharma VP of Biostatistics Joins MMS as Principal Advisor of Biostatistics and Submissions Planning

Nov 19, 2021

November 19, 2021 09:01 AM Eastern Standard Time CANTON, Mich.--( BUSINESS WIRE )--MMS Holdings – a data-focused CRO – announced this week the addition of Kevin Chartier, Ph.D., as Principal Advisor of Biostatistics and Submissions Planning. Chartier will work with the biostatistics team across MMS global operations to support Sponsors with complex studies and submissions. Bringing more than 25 years of statistics experience, Dr. Chartier has held positions at Astellas Pharma, Novartis, Wyeth, Pfizer, and United BioSource Corporation across various statistics, biometrics, and biostatistics functions. In addition, he completed his Ph.D. in Statistics from Kansas State University. “At MMS, we pride ourselves on being able to provide our Sponsors with the right experts to meet their goals,” said Michelle Gayari, Executive Vice President, Global Operational Excellence and Innovation, MMS. “With the addition of Dr. Chartier and his extensive experience in biostatistics and submissions planning to our global team, we continue to build on our best-in-class clinical trial design and data solutions for Sponsors and patients.” Dr. Chartier’s responsibilities as Principal Advisor of Biostatistics and Submissions Planning include: Acting as the senior technical reviewer for complex biostatistics studies Advising Sponsors on biostatistics methods and efficiencies for health authority submissions Contributing to MMS’ emerging biometrics service areas, data science using real world evidence and built-for-purpose technology, Datacise™ , adaptive trial design, and decentralized clinical trials (DCTs) Leading complex biostatistics studies, programs and submissions across therapeutic areas and extending to rare diseases “I am excited to join an organization with a proven track record, being able to get closer to the science and the data, and consulting with other drug developers,” said Dr. Kevin Chartier. “I plan on building upon this success and strive to provide MMS Sponsors with innovative fit-for-purpose quantitative development strategies and study options to ensure optimal decision making. I'm looking forward to providing educational opportunities for MMS colleagues and Sponsors who desire these services as well.” Additionally, Dr. Chartier will continue his mission of ensuring statistical and quantitative experts are full drug development partners shaping the evolution of drug development. MMS was recently named a Detroit Free Press Top Workplace in 2021. Learn more about MMS at www.mmsholdings.com/ About MMS Holdings MMS is an award-winning, data-focused CRO that supports the pharmaceutical, biotech, and medical device industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet rigorous regulatory standards. With a global footprint across four continents, MMS maintains a 97 percent customer satisfaction rating, and the company was named Most Outstanding CRO in the 2019 Biotechnology Awards and was named a Detroit Free Press Top Workplace in 2021. For more information, visit www.mmsholdings.com or follow MMS on LinkedIn . Contacts

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

United BioSource Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

United BioSource Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.